How much do Ga-, Lu- and I-based radiopharmaceuticals contribute to the global radiation exposure of nuclear medicine staff?

Background: The radiation exposure of nuclear medicine personnel, especially concerning extremity doses, has been a significant focus over the past two decades. This study addresses the evolving practice of NM, particularly with the rise of radionuclide therapy and theranostic procedures, which involve a variety of radionuclides such as Ga, Lu, and I. Traditional studies have concentrated on common radioisotopes like Tc, F, and Y, but there is limited data on these radionuclides, which are more and more frequently used.

Potential application of [F]AlF-PSMA-11 PET/CT in radioiodine refractory thyroid carcinoma.

Background: Patients diagnosed with radioiodine refractory (RAI-R) thyroid carcinoma (TC) have a significantly worse prognosis than patients with radiosensitive TC. These refractory malignancies are often dedifferentiated, hindering the effectiveness of iodine-based imaging. Additionally, the role of metabolic imaging using [F]FDG PET/CT is also limited in these cases, making adequate staging of RAI-R TC challenging.

Direct co-registration of [F]FDG uptake and histopathology in surgically excised malignancies of the head and neck: a feasibility study.

Purpose: Recent technical advancements in PET imaging have improved sensitivity and spatial resolution. Consequently, clinical nuclear medicine will be confronted with PET images on a previously unfamiliar resolution. To better understand [F]FDG distribution at submillimetric scale, a direct correlation of radionuclide-imaging and histopathology is required.

F-PSMA-11 Versus Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer: A Prospective Double-blind Randomised Cross-over Trial.

Background: Fluorine-18 (F)-labelled prostate-specific membrane antigen (PSMA) offers several advantages over gallium-68 (Ga) in terms of costs, yield, transport/distribution, and image resolution.

Objective: This trial investigates the new radiotracer F-PSMA-11 via a prospective, intraindividual crossover design. The trial was powered for noninferiority of F-PSMA-11 over Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT) in terms of the number of positive PET scans.

Impact of F-PSMA-11 PET/CT on Management of Biochemical Recurrence and High-Risk Prostate Cancer Staging : F-PSMA-11 PET/CT and Impact on Prostate Cancer Management.

Purpose: In this study, we evaluated the impact of F-PSMA-11 PET/CT on the patient management plan in patients with primary or recurrent disease. Furthermore, a correlation between PET findings and other modalities was performed.

Procedures: In this prospective observational study, 60 prostate cancer patients (9 primary staging, 51 biochemical recurrence) were imaged with F-PSMA-11 PET/CT.